This feature highlights changes in clinical research organizations’ personnel.
Leslie Donato has been named executive vice president and chief strategy officer at AmerisourceBergen. Donato was previously vice president of strategy at Bayer Pharmaceuticals.
Aperiomics has named Alexander Valencia chief clinical officer. Valencia previously served as the molecular laboratory director at Cincinnati Children’s Hospital Medical Center and PerkinElmer Genomics.
Ronald Peck has been appointed as the first chief medical officer at Arvinas. Peck was most recently senior vice president of clinical research at Tesaro.
Avexis has named Page Bouchard chief science officer. Bouchard previously served as global head of preclinical safety for parent company Novartis Institutes.
Cerevel Theraputics has named Orly Mishan as chief business officer. Mishan most recently served as principal of Bain Capital Life Sciences.
Reinhard von Roemeling has been named senior vice president of clinical development, and Christine Guertin has been named vice president of regulatory affairs and quality assurance. Roemeling was previously global head of research and development at Huya Bioscience International, and Guertin was the head of regulatory affairs at Synlogic and director of regulatory affairs at Array BioPharma.
Priti Hedge has been named chief science officer at Foundation Medicine. Hedge was most recently senior director and principal scientist in oncology biomarker development at Genentech.
Imara has appointed Eleanor Lisbon as vice president of clinical development, Farah Natoli as president of program management, Dora Rau as vice president of quality assurance, Anita Treohan as vice president of development operations, and Frank Waligora as vice president of technical operations.
Lisbon formerly served as the senior medical director within the hematology and oncology division of the data sciences, safety and regulatory team at IQVIA. Natoli served as the executive director of program and alliance leadership and humanitarian aid program at Bioverativ. Rau served as the vice president of global quality at Sucampo Pharmaceuticals. Treohan served as the senior director of portfolio and program management at Axcella Health. Waligora previously served as the vice president of chemistry, manufacturing and controls at Curis.
Robert Zeldin has been appointed chief medical officer at Immunovant. Zeldin was previously the chief medical officer at Acceleron Pharma.
Isofol has named Roger Tell chief medical officer. Tell came from Aprea Therapeutics where he was vice president of clinical development.
Matthew Call has been appointed chief operating officer at iTeos Theraputics SA. Call was most recently chief operating officer at Endocyte.
Christi Shaw has been appointed chief executive officer at Kite Pharma. Shaw was previously senior vice president of Eli Lilly & Co. and president of Lilly Bio-Medicines.
M2Gen has announced the appointment of Helge Bastian as president and chief executive officer. Bastian was formerly vice president and general manager of synthetic biology at Thermo Fisher Scientific.
Patrick McIntyre has been appointed chief executive officer at OneOme. McIntyre was previously president and founder of Portage Health Insights.
Anthony Lembo has been appointed to the medical advisory board at Ritter Pharmaceuticals. Lembo is a director of the GI mobility and functional bowel disorder center at Beth Israel Deaconess Medical Center and a professor of medicine at Harvard Medical School.
Springworks Theraputics has named Frank Perier as chief financial officer. Perier most recently served as the chief financial officer of Forest Laboratories.
Strongbridge Biopharma has named Richard Kollender as chief operating officer and Robert Lutz as chief financial officer. Kollender most recently served as principal and partner of Quaker Partners Management, a healthcare investment firm, and Lutz worked in management at Shire Pharmecuticals.
Todos Medical has named Paula Trzepacz chief medical officer of breakthrough diagnostics. Trzepacz served previously as a senior medical fellow in neurosciences at Eli Lilly & Co.
Helena Chaye has been named chief executive officer of Western Oncolytics. Chaye was most recently chief business officer and part of the strategic planning and development team at SillaJen Biotherapeutics.